Journal
CLINICAL CANCER RESEARCH
Volume 21, Issue 14, Pages 3102-3104Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-15-0363
Keywords
-
Categories
Funding
- NCI NIH HHS [K08CA160692, U54CA163125, K08 CA160692, U54 CA163125] Funding Source: Medline
Ask authors/readers for more resources
BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma. (C) 2015 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
